Portal vein thrombosis and arterioportal shunts: Effects on tumor response after chemoembolization of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 17, Issue 10, 2011, Pages 1267-1275

  Vogl, Thomas J ^a   Nour Eldin, Nour Eldin ^a   Emad Eldin, Sally ^a   Naguib, Nagy Nn ^a   Trojan, Joerg ^a   Ackermann, Hans ^b   Abdelaziz, Omar ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Cairo University   (Egypt)

Author keywords

Hepatocellular carcinoma; Portal; Shunt; Thrombosis; Transarterial chemoembolization

Indexed keywords

GADOLINIUM PENTETATE; IODINATED POPPYSEED OIL; MICROSPHERE; MITOMYCIN C; STARCH;

ADULT; AGED; ARTERIOVENOUS SHUNT; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; HEPATIC ARTERY; HUMAN; IMAGING SYSTEM; LIVER CELL CARCINOMA; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PORTAL VEIN; PORTAL VEIN THROMBOSIS; RETROSPECTIVE STUDY; SOLID TUMOR; SURVIVAL RATE; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79955938892     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i10.1267     Document Type: Article

References (31)

1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 Suppl 1: S20-S37
2. Llovet JM, Sala M. Non-surgical therapies of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17: 505-513
3. Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi S. Local recurrence of hepatocellular carcinoma after percutaneous ethanolinjection. Cancer 1996; 77: 1792-1796
4. Sartori S, Tombesi P, Macario F, Nielsen I, Tassinari D, Catellani M, Abbasciano V. Subcapsular liver tumors treated with percutaneous radiofrequency ablation: a prospective comparison with nonsubcapsular liver tumors for safety and effectiveness. Radiology 2008; 248: 670-679
5. Ishida T, Murakami T, Shibata T, Inoue Y, Takamura M, Niinobu T, Sato T, Nakamura H. Percutaneous microwave tumor coagulation for hepatocellular carcinomas with interruption of segmental hepatic blood flow. J Vasc Interv Radiol 2002; 13: 185-191
6. Vogl TJ, Straub R, Eichler K, Woitaschek D, Mack MG. Malignant liver tumors treated with MR imaging-guided laserinduced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002; 225:367-377
7. Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, Benjamin MS, Sherman M, Gallinger S, Burnett B, Feld R, Chen E, Greig PD, Grant DR, Knox JJ. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol) 2006; 18: 684-692
8. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469
9. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54
10. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
11. Zhang JW, Feng XY, Liu HQ, Yao ZW, Yang YM, Liu B, Yu YQ. CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE. World J Gastroenterol 2010; 16: 2038-2045
12. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guide lines. J Vasc Interv Radiol 2003; 227: 407-413
13. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001; 74: 983-986
14. Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004; 13: 1555-1568
15. Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2008; 14: 6437-6441
16. Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, Federico P, Buonerba C, Salvatore B, Marinelli A, Palmieri G. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient. Int J Immunopathol Pharmacol 2010; 23: 951-954
17. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240
18. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 54-58
19. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442
20. O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003; 90: 325-331
21. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
22. Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F, de Moura MC. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006; 26: 680-687
23. Ikeda M, Okada S, Yamamoto S, Sato T, Ueno H, Okusaka T, Kuriyama H, Takayasu K, Furukawa H, Iwata R. Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Jpn J Clin Oncol 2002; 32: 455-460
24. Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 2000; 73: 1178-1184
25. Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009; 29: 1291-1298
26. Kothary N, Weintraub JL, Susman J, Rundback JH. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 2007; 18: 1517-1526; quiz 1527
27. Kiely JM, Rilling WS, Touzios JG, Hieb RA, Franco J, Saeian K, Quebbeman EJ, Pitt HA. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 2006; 17: 47-53
28. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659
29. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995; 165: 315-321
30. Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol 1997; 52: 36-40
31. Huang MS, Lin Q, Jiang ZB, Zhu KS, Guan SH, Li ZR, Shan H. Comparison of long-term effects between intraarterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 825-829